Iovance Biotherapeutics (0JDK) Share Forecast & Price Target

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0JDK Analyst Ratings

Moderate Buy

5 Buy

2 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Iovance

Biotherapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0JDK Stock 12 Month Forecast

Average Price Target

$9.14

▲(94.94% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Iovance Biotherapeutics in the last 3 months. The average price target is $9.14 with a high forecast of $13.00 and a low forecast of $6.00. The average price target represents a 94.94% change from the last price of $4.69.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","14":"$14","3.5":"$3.5","10.5":"$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.142857142857142,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.12,4.803076923076923,5.486153846153846,6.169230769230769,6.852307692307692,7.535384615384615,8.218461538461538,8.901538461538461,9.584615384615384,10.267692307692307,10.95076923076923,11.633846153846154,12.316923076923075,{"y":13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.12,4.506373626373627,4.892747252747252,5.279120879120879,5.665494505494506,6.051868131868131,6.438241758241758,6.8246153846153845,7.21098901098901,7.597362637362637,7.983736263736263,8.370109890109891,8.756483516483517,{"y":9.142857142857142,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.12,4.264615384615385,4.40923076923077,4.553846153846154,4.6984615384615385,4.843076923076923,4.987692307692308,5.132307692307693,5.276923076923077,5.421538461538462,5.5661538461538465,5.71076923076923,5.855384615384615,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.595,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.213,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.229,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.969,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.279,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.585,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.42,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.47,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.938,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$13.00

Average Price Target$9.14

Lowest Price Target$6.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Nicholas Lorusso

TD Cowen

$7→$10

Buy

113.22%

Upside

Assigned

08/25/26

Lorusso Boosts Iovance Biotherapeutics Price Target to $10 on Strong Amtagvi Momentum and Operational Upside, Reaffirms Buy Rating

David Dai

UBS

$4→$7

Hold

49.25%

Upside

Assigned

08/20/26

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), CervoMed (NASDAQ: CRVO) and Korro Bio (NASDAQ: KRRO)

Salim Syed

Mizuho Securities

$10→$11

Buy

134.54%

Upside

Reiterated

08/17/26

Mizuho Securities Remains a Buy on Iovance Biotherapeutics (IOVA)

Etzer Darout

Barclays

$11→$13

Buy

177.19%

Upside

Reiterated

08/07/26

Barclays Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

Colleen M. Kusy

Robert W. Baird

$4→$6

Hold

27.93%

Upside

Reiterated

08/07/26

Iovance Biotherapeutics price target raised to $6 from $4 at BairdIovance Biotherapeutics price target raised to $6 from $4 at Baird

Reni Benjamin

Citizens JMP

$5→$8

Buy

70.58%

Upside

Reiterated

08/07/26

Iovance Biotherapeutics price target raised to $8 from $5 at CitizensIovance Biotherapeutics price target raised to $8 from $5 at Citizens

Joseph Pantginis

H.C. Wainwright

Buy

91.90%

Upside

Reiterated

08/06/26

Iovance: Strong AMTAGVI Execution and Global Expansion Support Buy Rating with Unchanged $9 Price Target

Geulah Livshits

Chardan Capital

$14

Buy

198.51%

Upside

Reiterated

05/07/26

Iovance Biotherapeutics price target lowered to $14 from $16 at ChardanIovance Biotherapeutics price target lowered to $14 from $16 at Chardan

Yanan Zhu

Wells Fargo

$14

Buy

198.51%

Upside

Reiterated

02/25/26

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)

Asthika Goonewardene

Truist Financial

―

Hold

―

Reiterated

02/25/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Erasca (NASDAQ: ERAS) and Tempus AI, Inc. Class A (NASDAQ: TEM)

Andrea Newkirk

Goldman Sachs

$1.5→$2

Sell

-57.36%

Downside

Reiterated

02/05/26

Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman SachsIovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Nicholas Lorusso

TD Cowen

$7→$10

Buy

113.22%

Upside

Assigned

08/25/26

Lorusso Boosts Iovance Biotherapeutics Price Target to $10 on Strong Amtagvi Momentum and Operational Upside, Reaffirms Buy Rating

David Dai

UBS

$4→$7

Hold

49.25%

Upside

Assigned

08/20/26

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), CervoMed (NASDAQ: CRVO) and Korro Bio (NASDAQ: KRRO)

Salim Syed

Mizuho Securities

$10→$11

Buy

134.54%

Upside

Reiterated

08/17/26

Mizuho Securities Remains a Buy on Iovance Biotherapeutics (IOVA)

Etzer Darout

Barclays

$11→$13

Buy

177.19%

Upside

Reiterated

08/07/26

Barclays Sticks to Its Buy Rating for Iovance Biotherapeutics (IOVA)

Colleen M. Kusy

Robert W. Baird

$4→$6

Hold

27.93%

Upside

Reiterated

08/07/26

Iovance Biotherapeutics price target raised to $6 from $4 at BairdIovance Biotherapeutics price target raised to $6 from $4 at Baird

Reni Benjamin

Citizens JMP

$5→$8

Buy

70.58%

Upside

Reiterated

08/07/26

Iovance Biotherapeutics price target raised to $8 from $5 at CitizensIovance Biotherapeutics price target raised to $8 from $5 at Citizens

Joseph Pantginis

H.C. Wainwright

Buy

91.90%

Upside

Reiterated

08/06/26

Iovance: Strong AMTAGVI Execution and Global Expansion Support Buy Rating with Unchanged $9 Price Target

Geulah Livshits

Chardan Capital

$14

Buy

198.51%

Upside

Reiterated

05/07/26

Iovance Biotherapeutics price target lowered to $14 from $16 at ChardanIovance Biotherapeutics price target lowered to $14 from $16 at Chardan

Yanan Zhu

Wells Fargo

$14

Buy

198.51%

Upside

Reiterated

02/25/26

Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (NASDAQ: IOVA), BioMarin Pharmaceutical (NASDAQ: BMRN) and Kiniksa Pharmaceuticals (NASDAQ: KNSA)

Asthika Goonewardene

Truist Financial

―

Hold

―

Reiterated

02/25/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Erasca (NASDAQ: ERAS) and Tempus AI, Inc. Class A (NASDAQ: TEM)

Andrea Newkirk

Goldman Sachs

$1.5→$2

Sell

-57.36%

Downside

Reiterated

02/05/26

Iovance Biotherapeutics price target raised to $2 from $1.50 at Goldman SachsIovance Biotherapeutics price target raised to $2 from $1.50 at Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

IMMXImmix Biopharma

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Iovance Biotherapeutics

3 Months

Joseph PantginisH.C. Wainwright

Success Rate

13/14 ratings generated profit

Average Return

+30.14%

Copying Joseph Pantginis's trades and holding each position for 3 Months would result in 92.86% of your transactions generating a profit, with an average return of +30.14% per trade.

1 Year

Joseph PantginisH.C. Wainwright

Success Rate

13/14 ratings generated profit

Average Return

+158.42%

Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 92.86% of your transactions generating a profit, with an average return of +158.42% per trade.

2 Years

Joseph PantginisH.C. Wainwright

Success Rate

14/14 ratings generated profit

Average Return

+218.42%

Copying Joseph Pantginis's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +218.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0JDK Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0JDK has received 11 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 0JDK average Analyst price target in the past 3 months is 9.14.

Each month's total comprises the sum of three months' worth of ratings.

0JDK Financial Forecast

0JDK Earnings Forecast

Next quarter’s earnings estimate for 0JDK is -$0.09 with a range of -$0.12 to -$0.08. The previous quarter’s EPS was -$0.11. 0JDK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0JDK has Performed in-line its overall industry.

0JDK Sales Forecast

Next quarter’s sales forecast for 0JDK is $110.12M with a range of $101.46M to $119.00M. The previous quarter’s sales results were $99.31M. 0JDK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0JDK has Performed in-line its overall industry.

0JDK Stock Forecast FAQ

What is GB:0JDK’s average 12-month price target, according to analysts?

Based on analyst ratings, Iovance Biotherapeutics Inc’s 12-month average price target is 9.14.

What is GB:0JDK’s upside potential, based on the analysts’ average price target?

Iovance Biotherapeutics Inc has 94.94% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Iovance Biotherapeutics Inc a Buy, Sell or Hold?

Iovance Biotherapeutics Inc has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 2 hold ratings and 0 sell ratings.

What is Iovance Biotherapeutics Inc’s share price target?

The average share price target for Iovance Biotherapeutics Inc is 9.14. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $13.00 ,and the lowest forecast is $6.00. The average share price target represents 94.94% Increase from the current price of $4.69.

What do analysts say about Iovance Biotherapeutics Inc?

Iovance Biotherapeutics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of Iovance Biotherapeutics Inc?

To buy shares of GB:0JDK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Iovance Biotherapeutics (0JDK) Share Forecast & Price Target

0JDK Analyst Ratings

0JDK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Iovance Biotherapeutics

0JDK Analyst Recommendation Trends

0JDK Financial Forecast

0JDK Earnings Forecast

0JDK Sales Forecast

0JDK Stock Forecast FAQ

Detailed List of Analyst Forecasts